In HCC patients with elevated alpha-fetoprotein prior to treatment and who had previously progressed on sorafenib or were considered not eligible to receive sorafenib, galunisertib monotherapy achieved a median OS of 7.3 months (95% CI, 4.9–10.5). The gene discussed is AFP; the disease is hepatocellular carcinoma.